CClinicalTrials.gg
CompletedNCT05381675Updated Aug 29, 2023

Short Term Results of Tele-Rehabilitation

An interventional study of Tele-rehabillitation and Prescribed Exercise Program in COVID-19 and Dyspnea, sponsored by Harran University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-29.

Sponsored by Harran University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Most people who have coronavirus disease (COVID-19) recover completely without any sequelae. However, some patients continue to experience symptoms of COVID-19 even though their tests turn negative. This clinical spectrum that occurs after acute infection is called the post-COVID syndrome (PCS). Dyspnea, pain, decreased exercise capacity, limitations in activities of daily living, poor sleep quality, anxiety and depression are common symptoms in PCS. The aim of our study is to examine the effect of tele-rehabilitation-based exercise program on dyspnea, pain, functional capacity, sleep quality, anxiety and depression in individuals with PCS.

02

Conditions studied

  • COVID-19
  • Dyspnea

Browse trials for

Keywords

  • Tele-rehabilitation
  • COVID-19
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 60 is below the median of 100 across 4,099 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Harran University is the lead sponsor of 60 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Being between the ages of 18-75,
  • Being in stable medical condition, conscious and cooperative,
  • Having had COVID and continuing symptoms
  • Volunteering to participate in the study,
  • Own a device that can be connected online independently or with support from family members.

Exclusion criteria

Exclusion Criteria:

SpO2 \< 92%,

  • Hypotension (Systolic Blood Pressure \< 90 mmHg or Diastolic Blood Pressure \< 60mmHg)
  • Having chronic respiratory disease (COPD, Asthma, etc.)
  • Having a stroke or neurodegenerative disease.
  • Not being willing to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Intervention

    Participants will receive a supervised tele-rehabilitation program 2 days a week for 6 weeks.

    Other: Tele-rehabillitation

  • Other
    Control

    Participants will receive the same rehabilitation program as prescribed.

    Other: Prescribed Exercise Program

Interventions

  • OtherTele-rehabillitation

    Tele-rehabilitation program will be performed by physiotherapist two times a week for six consecutive weeks. Program including the following exercises: Breathing exercises Aerobic exercises Flexibility Strengthening exercises

  • OtherPrescribed Exercise Program

    The prescribed exercise program will be performed two times a week for six consecutive weeks. Program including the following exercises: Breathing exercises Aerobic exercises Flexibility Strengthening exercises

06

What researchers measure

Primary outcomes

  1. Change from the baseline to the 6th week in mMRC (Modified Medical Research Council) Dyspnoea Scale

    The mMRC Dyspnoea Scale is used to assess the degree of baseline functional disability due to dyspnoea

    Time frame: Baseline and 6th week

Secondary outcomes

  1. Change from the baseline to the 6th week in NPRS

    The Numerical Rating Scale (NPRS-11) is an 11-point scale for self-report of pain. It is the most commonly used unidimensional pain scale. The respondent selects a whole number (integers 0-10) that best reflects the intensity (or other quality if requested of his/her pain.

    Time frame: Baseline and 6th week

  2. Change from the baseline to the 6th week in the 5 times sit to stand test (5XSST)

    The 5XSST scoring is based on the amount of time (to the nearest decimal in seconds) a patient is able to transfer from a seated to a standing position and back to sitting five times. The equipment need in performing 5XSST test includes: Stopwatch and standard height chair with straight back.

    Time frame: Baseline and 6th week

  3. Change from the baseline to the 6th week in the Hospital Anxiety and Depression Scale

    The Hospital Anxiety and Depression Scale (HADS) was devised to measure anxiety and depression in a general medical population of patients. The questionnaire comprises seven questions for anxiety and seven questions for depression, and takes 2-5min to complete. Although the anxiety and depression questions are interspersed within the questionnaire, it is vital that these are scored separately.

    Time frame: Baseline and 6th week

  4. Change from the baseline to the 6th week in the The Pittsburgh Sleep Quality Index

    The Pittsburgh Sleep Quality Index (PSQI) is a measure of self-reported sleep quality and sleep disturbance. Scoring Using a four-point, Likert-type scale, respondents indicate how frequently they exhibit certain sleep behaviors (0 = "few," 1 = "some- times," 2 = "often," and 3 = "almost always"). The PSQI takes about 10 minutes to complete and it doesn't involve any procedures or interventions.

    Time frame: Baseline and 6th week

07

Study locations

1 site
  • İstanbul University-Cerrahpasa
    Istanbul, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05381675
Lead sponsor
Harran University
Responsible party
Zeynal Yasacı (Research Assistant, Harran University) — Principal investigator
First posted
May 19, 2022
Start date
May 20, 2022
Primary completion
May 20, 2023
Completion
Aug 1, 2023
Last update
Aug 29, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion